ArticleScientific reports2025
NT-proCNP as a new biomarker of pulmonary hypertension in patients with COPD.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Cardiac biomarkers in athletes and active individuals: a clinical review of exercise-induced elevations and diagnostic interpretation.Frontiers in physiology · 2026Review
- Construction of nomogram for predicting pulmonary hypertension on echocardiography in chronic obstructive pulmonary disease: a single-center retrospective study.Open medicine (Warsaw, Poland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To assess N-Terminal Pro C-Type Natriuretic Peptide (NT-proCNP) plasma levels in patients with chronic obstructive pulmonary disease (COPD) and evaluate of its diagnostic value for pulmonary hypertension (PH) in COPD. According to the range of systolic pulmonary artery pressure (SPAP), the COPD patients were divided into group of patients without PH (SPAP < 40 mmHg, n = 42) and group of patients with PH (SPAP ≥40 mmHg, n = 52). Significant differences in NT-proCNP levels were found in patients with and without PH (3.63 ± 0.95 pg/mL vs. 1.42 ± 0.35 pg/mL, p < 0.001). Statistically significant correlations were shown between NT-proCNP levels and SPAP (r = 0.77, p < 0.001), mMRC dyspnea score (r = 0.42, p = 0.001), CAT score (r = 0.60, p < 0.001), and SpO2 (r = − 0.47, p = 0.001). Pulmonary hypertension in COPD patients was associated with higher plasma NT-proCNP levels.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.